BIOT.SW L&G Pharma Breakthrough UCITS ETF USD Accumulating ETF

ETF Healthcare Equity LGIM Managers (Europe) Limited SIX Swiss Exchange
- CHF
No recent price
Total assets
24.9M
Expense ratio
0.50%
Dividend yield
-
1-year return
+20.60%
Holdings
10
Since
2018

Fund data as reported by the issuer, updated Oct 30, 2026. Total assets are in the fund's base currency.

What does BIOT.SW invest in?

Tracks Morningstar Gbl Biotechnology NR USD
  • Mostly US stocks (67.9%)
  • Largest sector: Healthcare (93.2%)
  • Largest region: North America (67.6%)
  • Top 3 holdings: 9.0% of the fund

Asset allocation

  • US stocks 67.9%
  • Non-US stocks 29.5%
  • Cash 0.2%

Top holdings

  • Xeris Pharmaceuticals Inc 3.16%
  • United Therapeutics Corporation 3.01%
  • Genmab A/S 2.84%
  • Rigel Pharmaceuticals Inc 2.73%
  • Recordati Industria Chimica e Farmaceutica S.p.A. 2.73%
All holdings, sectors and regions

L&G Pharma Breakthrough UCITS ETF USD Accumulating ETF performance

Sharpe ratio 0.42
This year
+15.96%
1 year
+20.60%
3 years
+13.52%
5 years
+1.30%

Volatility 17.5% over 1 year and 15.6% over 3 years. Moderate, similar to a broad stock index.

Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers

BIOT.SW price

Prices on the chart can differ slightly from the closing prices StockSummer shows.